Showing results (101-110 of 118) with videos related to
Sort By:
Pageof 12
Therapeutic Advances in Medical Oncology|July 21, 2020
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" studyDominique Arpin, Marie-Christine Charpentier, Marie Bernardi, et al.Mutagenesis|February 26, 2013
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesotheliomaPascal Andujar, Jean-Claude Pairon, Annie Renier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohortJulien Mazières, Gérard Zalcman, Lucio Crinò, et al.Lung Cancer (Amsterdam, Netherlands)|July 14, 2024
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study)Mathilde Jacob, Pierre Fournel, Claire Tissot, et al.JAMA Oncology|May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung CancerArianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.European Journal of Cancer (Oxford, England : 1990)|November 5, 2025
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerJessica Menis, Laurent Greiller, Pierre Demontrond, et al.Lancet (London, England)|January 19, 2016
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, et al.The European Respiratory Journal|September 29, 2018
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trialGuy Meyer, Benjamin Besse, Hélène Doubre, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2020
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung CancerSandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2021
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter RegistryAlexander Drilon, Michael Duruisseaux, Ji-Youn Han, et al.Pageof 12